EGFR突变在越南早期非小细胞肺癌切除术患者中的流行:早期EGFR研究

IF 5.1 Q1 ONCOLOGY
Lung Cancer: Targets and Therapy Pub Date : 2025-04-21 eCollection Date: 2025-01-01 DOI:10.2147/LCTT.S494554
Tu Van Dao, Van Luong Dinh, Thanh Vinh Doan, Tri Le Phuong
{"title":"EGFR突变在越南早期非小细胞肺癌切除术患者中的流行:早期EGFR研究","authors":"Tu Van Dao, Van Luong Dinh, Thanh Vinh Doan, Tri Le Phuong","doi":"10.2147/LCTT.S494554","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Comprehensive profiling of mutations in the <i>EGFR</i> gene is vital for selecting patients eligible for <i>EGFR</i> targeted therapies.</p><p><strong>Methods: </strong>We investigated the prevalence of <i>EGFR</i> mutations and treatment patterns in patients with early stage non-small cell lung cancer (NSCLC) in Vietnam as a part of EARLY-EGFR (Clinical Trial Identifier: NCT04742192), a global, real-world study. Consecutive patients with surgically resected stage IA-IIIB, non-squamous NSCLC were diagnosed from August 2021 to June 2022 and were prospectively enrolled from November 2021 to July 2022.</p><p><strong>Results: </strong>A total 200 patients (age: median [range], 60.0 [30.0-80.0] years) were enrolled from 3 centers; 56.0% were males and 64.0% never smoked. The prevalence of <i>EGFR</i> mutations was 51.0% (102/200) including deletions in <i>exon-19</i> (49.0%) and <i>exon-21 L858R</i> mutations (33.3%). Females (73.9%, 65/88), patients aged ≥60 years (52.5%, 53/101), nonsmokers (61.2%, 63/103) and those with stage I (55.8%, 67/120) had higher prevalence of <i>EGFR</i> mutations. Multivariate analysis (adjusted odds ratio [aOR]) showed <i>EGFR</i> mutations to be significantly associated (p < 0.05) with female gender (aOR = 5.90), age ≥60 years (aOR = 1.05), and stage III disease (vs stage I) (aOR = 0.30).</p><p><strong>Conclusion: </strong>These results underscore the need for <i>EGFR</i> testing early in management algorithm of NSCLC in Vietnam to identify patients eligible for targeted therapy in concordance with international guidelines.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":"16 ","pages":"39-49"},"PeriodicalIF":5.1000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12025828/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prevalence of <i>EGFR</i> Mutations in Vietnamese Patients with Resected Early Stage Non-Small Cell Lung Cancer: EARLY-EGFR Study.\",\"authors\":\"Tu Van Dao, Van Luong Dinh, Thanh Vinh Doan, Tri Le Phuong\",\"doi\":\"10.2147/LCTT.S494554\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Comprehensive profiling of mutations in the <i>EGFR</i> gene is vital for selecting patients eligible for <i>EGFR</i> targeted therapies.</p><p><strong>Methods: </strong>We investigated the prevalence of <i>EGFR</i> mutations and treatment patterns in patients with early stage non-small cell lung cancer (NSCLC) in Vietnam as a part of EARLY-EGFR (Clinical Trial Identifier: NCT04742192), a global, real-world study. Consecutive patients with surgically resected stage IA-IIIB, non-squamous NSCLC were diagnosed from August 2021 to June 2022 and were prospectively enrolled from November 2021 to July 2022.</p><p><strong>Results: </strong>A total 200 patients (age: median [range], 60.0 [30.0-80.0] years) were enrolled from 3 centers; 56.0% were males and 64.0% never smoked. The prevalence of <i>EGFR</i> mutations was 51.0% (102/200) including deletions in <i>exon-19</i> (49.0%) and <i>exon-21 L858R</i> mutations (33.3%). Females (73.9%, 65/88), patients aged ≥60 years (52.5%, 53/101), nonsmokers (61.2%, 63/103) and those with stage I (55.8%, 67/120) had higher prevalence of <i>EGFR</i> mutations. Multivariate analysis (adjusted odds ratio [aOR]) showed <i>EGFR</i> mutations to be significantly associated (p < 0.05) with female gender (aOR = 5.90), age ≥60 years (aOR = 1.05), and stage III disease (vs stage I) (aOR = 0.30).</p><p><strong>Conclusion: </strong>These results underscore the need for <i>EGFR</i> testing early in management algorithm of NSCLC in Vietnam to identify patients eligible for targeted therapy in concordance with international guidelines.</p>\",\"PeriodicalId\":18066,\"journal\":{\"name\":\"Lung Cancer: Targets and Therapy\",\"volume\":\"16 \",\"pages\":\"39-49\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2025-04-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12025828/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lung Cancer: Targets and Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/LCTT.S494554\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer: Targets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/LCTT.S494554","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

全面分析EGFR基因突变对于选择适合EGFR靶向治疗的患者至关重要。方法:我们调查了越南早期非小细胞肺癌(NSCLC)患者中EGFR突变的患病率和治疗模式,作为早期EGFR(临床试验标识符:NCT04742192)的一部分,这是一项全球性的真实世界研究。于2021年8月至2022年6月诊断为手术切除的IA-IIIB期非鳞状NSCLC的连续患者,并于2021年11月至2022年7月前瞻性入组。结果:共纳入来自3个中心的200例患者(年龄:中位数[范围],60.0[30.0-80.0]岁);56.0%为男性,64.0%从不吸烟。EGFR突变发生率为51.0%(102/200),其中外显子19缺失(49.0%)和外显子21缺失L858R突变(33.3%)。女性(73.9%,65/88)、年龄≥60岁(52.5%,53/101)、非吸烟者(61.2%,63/103)和I期患者(55.8%,67/120)的EGFR突变发生率较高。多因素分析(校正优势比[aOR])显示,EGFR突变与女性(aOR = 5.90)、年龄≥60岁(aOR = 1.05)、III期疾病(aOR = 0.30)显著相关(p < 0.05)。结论:这些结果强调了在越南NSCLC的早期管理算法中进行EGFR检测的必要性,以确定符合国际指南的靶向治疗的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Prevalence of EGFR Mutations in Vietnamese Patients with Resected Early Stage Non-Small Cell Lung Cancer: EARLY-EGFR Study.

Introduction: Comprehensive profiling of mutations in the EGFR gene is vital for selecting patients eligible for EGFR targeted therapies.

Methods: We investigated the prevalence of EGFR mutations and treatment patterns in patients with early stage non-small cell lung cancer (NSCLC) in Vietnam as a part of EARLY-EGFR (Clinical Trial Identifier: NCT04742192), a global, real-world study. Consecutive patients with surgically resected stage IA-IIIB, non-squamous NSCLC were diagnosed from August 2021 to June 2022 and were prospectively enrolled from November 2021 to July 2022.

Results: A total 200 patients (age: median [range], 60.0 [30.0-80.0] years) were enrolled from 3 centers; 56.0% were males and 64.0% never smoked. The prevalence of EGFR mutations was 51.0% (102/200) including deletions in exon-19 (49.0%) and exon-21 L858R mutations (33.3%). Females (73.9%, 65/88), patients aged ≥60 years (52.5%, 53/101), nonsmokers (61.2%, 63/103) and those with stage I (55.8%, 67/120) had higher prevalence of EGFR mutations. Multivariate analysis (adjusted odds ratio [aOR]) showed EGFR mutations to be significantly associated (p < 0.05) with female gender (aOR = 5.90), age ≥60 years (aOR = 1.05), and stage III disease (vs stage I) (aOR = 0.30).

Conclusion: These results underscore the need for EGFR testing early in management algorithm of NSCLC in Vietnam to identify patients eligible for targeted therapy in concordance with international guidelines.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
8.10
自引率
0.00%
发文量
10
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信